Novonesis raises growth outlook after strong quarter

Danish biotech group Novonesis raised its full-year outlook after a strong second quarter. The company now expects organic revenue growth between 7 and 8 percent this year. Its previous target was between 5 and 7 percent growth.

For the second quarter, revenue reached 1,116.2 million euros. Analysts had expected revenue of 1,100.9 million euros. The Danish group exceeded these market forecasts. This information was reported by The Copenhagen Post.